Well, investors, NuVasive (NASDAQ: NUVA) just couldn't wait to tell you the good news. Ahead of its presentation at the JPMorgan Healthcare Conference and its official Q4 earnings press release, the company revealed its full year 2012 revenue results. In this video, health care analyst Max Macaluso discusses why this news drove shares up by more than 10% and what investors should watch in 2013.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.